Abstract
Aim:
To establish a cell-based assay to screen human dopamine D1 and D5 receptor agonists against compounds from a natural product compound library.
Methods:
Synthetic responsive elements 6×cAMP response elements (CRE) and a mini promoter containing a TATA box were inserted into the pGL3 basic vector to generate the reporter gene construct pCRE/TA/Luci. CHO cells were co-transfected with the reporter gene construct and human D1 or D5 receptor cDNA in mammalian expression vectors. Stable cell lines were established for agonist screening. A natural product compound library from over 300 herbs has been established. The extracts from these herbs were used for human D1 and D5 receptor agonist screenings.
Results:
A number of extracts were identified that activated both D1 and D5 receptors. One of the herb extracts, SBG492, demonstrated distinct pharmacological characteristics with human D1 and D5 receptors. The EC50 values of SBG492 were 342.7 μg/mL for the D1 receptor and 31.7 μg/mL for the D5 receptor.
Conclusion:
We have established a cell-based assay for high-throughput drug screening to identify D1-like receptor agonists from natural products. Several extracts that can active D1-like receptors were discovered. These compounds could be useful tools for studies on the functions of these receptors in the brain and could potentially be developed into therapeutic drugs for the treatment of central nervous system diseases.
Similar content being viewed by others
Article PDF
References
Braun AR, Laruelle M, Mouradian MM . Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J Neural Transm 1997; 104: 341–62.
Vallone D, Picetti R, Borrelli E . Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24: 125–32.
Meyer ME, Cottrell GA, Van Hartesveldt C, Potter TJ . Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats. Pharmacol Biochem Behav 1993; 44: 429–32.
Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S . Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999; 84: 133–56.
Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, Graybiel AM, et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 1994; 79: 729–42.
El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR . Spatial learning deficit in dopamine D(1) receptor knockout mice. Eur J Pharmacol 1999; 383: 95–106.
Centonze D, Grande C, Saulle E, Martin AB, Gubellini P, Pavon N, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 2003; 23: 8506–12.
Lidow MS, Koh PO, Arnsten AF . D1 dopamine receptors in the mouse prefrontal cortex: immunocytochemical and cognitive neuropharmacological analyses. Synapse 2003; 47: 101–8.
Williams GV, Goldman-Rakic PS . Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376: 572–5.
Hurley MJ, Mash DC, Jenner P . Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease. Brain Res Mol Brain Res 2001; 87: 271–9.
Mailman R, Huang X, Nichols DE . Parkinson's disease and D1 dopamine receptors. Curr Opin Invest Drugs 2001; 2: 1582–91.
Hersi AI, Kitaichi K, Srivastava LK, Gaudreau P, Quirion R . Dopamine D-5 receptor modulates hippocampal acetylcholine release. Brain Res Mol Brain Res 2000; 76: 336–40.
Castellano C, Cestari V, Cabib S, Puglisi-Allegra S . Post-training dopamine receptor agonists and antagonists affect memory storage in mice irrespective of their selectivity for D1 or D2 receptors. Behav Neural Biol 1991; 56: 283–91.
Castner SA, Goldman-Rakic PS . Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci 2004; 24: 1446–50.
Linazasoro G . Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 2004; 251: 335–9.
Jenner P . Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease. Curr Opin Neurol 2003; 16 Suppl 1: 3–7.
Ruggieri S, Stocchi F, Baronti F, Viselli F, Horowski R, Lucarelli C, et al. Antagonist effect of terguride in Parkinson's disease. Clin Neuropharmacol 1991; 14: 450–6.
Meyer ME, Van Hartesveldt C, Potter TJ . Locomotor activity following intra-accumbens microinjections of dopamine D1 agonist SK&F 38393 in rats. Synapse 1993; 13: 310–4.
Kariv II, Stevens ME, Behrens DL, Oldenburg KR . High throughput quantitation of camp production mediated by activation of seven transmembrane domain receptors. J Biomol Screen 1999; 4: 27–32.
Fitzgerald LR, Mannan IJ, Dytko GM, Wu HL, Nambi P . Measurement of responses from Gi-, Gs-, or Gq-coupled receptors by a multiple response element/cAMP response element-directed reporter assay. Anal Biochem 1999; 275: 54–61.
George SE, Bungay PJ, Naylor LH . Functional analysis of the D2L dopamine receptor expressed in a cAMP-responsive luciferase reporter cell line. Biochem Pharmacol 1998; 56: 25–30.
Hertzberg RP, Pope AJ . High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 2000; 4: 445–51.
Jiang C, Chen G, Zeng X, Ouyang K, Hu Y . Generation of a bioactive neuropeptide in a cell-free system. Anal Biochem 2003; 316: 34–40.
Gilmore JH, Watts VJ, Lawler CP, Noll EP, Nichols DE, Mailman RB . “Full” dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications. Neuropharmacology 1995; 34: 481–8.
Grandy DK, Zhang YA, Bouvier C, Zhou QY, Johnson RA, Allen L, et al. Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci USA 1991; 88: 9175–9.
Zhang JH, Chung TD, Oldenburg KR . A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67–73.
Sidhu A . Coupling of D1 and D5 dopamine receptors to multiple G proteins: Implications for understanding the diversity in receptor- G protein coupling. Mol Neurobiol 1998; 16: 125–34.
Seeman P, van Tol HH . Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 1993; 6: 602–8.
Xu ZL, Gao H, Ou-Yang KQ, Cai SX, Hu YH . Establishment of a cell-based assay to screen regulators for Klotho gene promoter. Acta Pharmacol Sin 2004; 25: 1165–70.
Zheng XX, Ou-Yang KQ, Gao H, Xu ZL, Hu YH, Cai SX . Study on high throughput screening method of identifying agonist for neuromedin U2 receptor. Chin Pharm J 2004; 9: 185–8. Chinese.
Gao H, Ou-Yang KQ, Zheng XX, Xu ZL, Hu YH, Cai SX . High throughput screening method of identifying agonist for muscarinic receptor. Chin Pharmacol Bull 2003; 19: 776–9. Chinese.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by grants from the Shanghai Commission for Education, Shanghai Commission for Science and Technology, and the Ministry of Science and Technology of China (No 010231006, 2003CB716600).
Rights and permissions
About this article
Cite this article
Jiang, N., Ou-yang, Kq., Cai, Sx. et al. Identification of human dopamine D1-like receptor agonist using a cell-based functional assay. Acta Pharmacol Sin 26, 1181–1186 (2005). https://doi.org/10.1111/j.1745-7254.2005.00199.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00199.x
Keywords
This article is cited by
-
The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease
Naunyn-Schmiedeberg's Archives of Pharmacology (2009)